Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

Completed · Not applicable · Has a placebo group

Conditions studied: Low Bone Mass

In brief

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Key facts

Study ID

NCT06250283

Run by

University of Delaware

People needed

52

Starts

2024-02-02

Expected to finish

2026-01-30

Last updated by the study team

2026-05-13

Who can join

Age: any. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• 1 to 10 years postmenopausal women with low bone mass

You may not qualify if…

• Osteoporosis
• Taking blood thinners, endocrine, or neuroactive drugs
• Hormone therapy
• Diagnosed: Metabolic bone disease, renal disease, kidney stones, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease
• Severe menopausal symptoms, serious mood alterations, sleep disturbances
• Abnormal uterine bleeding, endometriosis, pelvic inflammatory disease
• Endometrial polyps, and significant uterine fibroids
• Smokers (≥ 20 cigarettes per day)
• BMI <20 and > 30 kg/m2
• Intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes, red wine, or blueberries

Where it is running

• University of Delaware — Newark, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.